AZD8630
Sponsors
AstraZeneca AB, AstraZeneca
Conditions
AsthmaAsthma in adults who remain uncontrolled despite medium to high dose ICS plus LABAand who are at risk of exacerbations.
Phase 1
A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists
CompletedNCT05110976
Start: 2021-12-16End: 2023-08-02Updated: 2023-08-30
A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma
CompletedNCT06795906
Start: 2025-01-28End: 2025-06-27Updated: 2025-10-03
A Study of Inhaled AZD8630 in Adolescents With Asthma
CompletedNCT07065331
Start: 2025-06-11End: 2025-09-19Updated: 2025-10-14
Phase 2
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
CompletedNCT06529419
Start: 2024-08-30End: 2026-02-04Updated: 2026-03-02
A Phase 2b, Randomised, Double-Blind, Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE).
Active, not recruitingCTIS2024-514228-18-00
Start: 2025-01-16Target: 110Updated: 2026-01-16